Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1641 1677 1678 1758 1787 1796
This examiner grants 59% of resolved cases
Examiner Counts operates in Art Unit 1641 with an allowance rate of 58.9% over 838 resolved cases. This moderate rate suggests that while grants are common, Tech Center 1700 maintains strict standards for patentability. The median days to allowance of 1151 indicates a prosecution cycle that typically lasts for an extended period. With 838 resolved cases, these figures represent a well-established and reliable pattern of examination behavior.
The most striking data point is the interview lift of 29.5%, which is exceptionally high. This suggests that for the 838 resolved cases, an interview was often the decisive factor in securing an allowance. Practitioners should consider an interview mandatory when working with this examiner, as it significantly improves the effectiveness of the prosecution effort compared to the 58.9% baseline allowance rate. Utilizing the 29.5% lift is the most effective way to navigate the 1151-day median timeline and improve the probability of success. This high lift indicates that the examiner is very responsive to verbal clarification and collaborative problem-solving.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18474826 | BIOMARKERS AND METHODS FOR DIFFERENTIATING BETWEEN MILD AND SUPERMILD TRAUMATIC BRAIN INJURY | Final Rejection | Abbott Laboratories |
| 18834684 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18251926 | AUTOANTIBODIES AS BIOMARKERS FOR LIPODYSTROPHY | Non-Final OA | The Regents of the University of California |
| 17595478 | REAGENTS FOR SANDWICH IMMUNOASSAYS USING PARTICLE ENHANCED AGGLUTINATION DETECTION AND METHODS OF PRODUCTION AND USE THEREOF | Non-Final OA | Siemens Healthcare Diagnostics Inc. |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 17772959 | SEPSIS MANAGEMENT | Non-Final OA | ROCHE DIAGNOSTICS OPERATIONS, INC. |
| 18339108 | NANO-LIGAND FOR PROMOTING CELL ADHESION AND DIFFERENTIATION OF STEM CELLS AND METHOD OF PROMOTING CELL ADHESION AND DIFFERENTIATION OF STEM CELLS BY USING THE SAME | Non-Final OA | Korea University Research and Business Foundation |
| 18672669 | QUANTIFICATION OF LOW AMOUNTS OF ANTIBODY SIDE-PRODUCTS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18279624 | BIOMARKER | Final Rejection | Oxford University Innovation Limited |
| 18840269 | PROTEIN BIOMARKERS OF INFLAMMATORY ACTIVITY IN MULTIPLE SCLEROSIS | Non-Final OA | The Board of Regents of the University of Oklahoma |
| 18157250 | METHOD OF ASSISTING DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE | Non-Final OA | OSAKA UNIVERSITY |
| 18276218 | MARKER FOR DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE | Final Rejection | BREXOGEN INC. |
| 18557941 | Biomarkers for Neurodegenerative Disease | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 17735555 | COMPOSITIONS AND METHODS FOR THE DETECTION OF HOST CELL PROTEINS | Final Rejection | LONZA LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy